PubMed:21635990 JSONTXT

{"target":"https://pubannotation.org/docs/sourcedb/PubMed/sourceid/21635990","sourcedb":"PubMed","sourceid":"21635990","source_url":"http://www.ncbi.nlm.nih.gov/pubmed/21635990","text":"Palonosetron versus other 5-HT(3) receptor antagonists for prevention of chemotherapy-induced nausea and vomiting in patients with cancer on chemotherapy in a hospital outpatient setting.\nBACKGROUND: Despite favorable evidence from clinical trials for single-dose palonosetron versus other commercially available 5-HT(3)-receptor antagonists for the prophylaxis of chemotherapy-induced nausea and vomiting (CINV), clinical comparative data are scarce from hospital outpatient settings, where these antiemetic agents are used in patients diagnosed with cancer who are receiving chemotherapy (CTH).\nOBJECTIVE: The purpose of our retrospective study was to assess the hospital claims to evaluate the rate of uncontrolled CINV with antiemetic prophylaxis using palonosetron versus other 5-HT(3)-receptor antagonists in patients diagnosed with cancer who are receiving CTH (highly emetogenic CTH, moderately emetogenic CTH, low-emetogenic CTH, or minimally emetogenic CTH) treatment in a hospital outpatient setting.\nMETHODS: Patients aged ≥18 years who had cancer and were being treated with CTH and antiemetic prophylaxis with palonosetron (Group 1) and other 5-HT(3) receptor antagonists (Group 2) for the first time between April 1, 2007, and March 31, 2009, were identified using a hospital-service database. Within each CTH cycle, CINV events were identified through International Classification of Diseases (ICD)-9 codes for nausea, vomiting, and/or volume depletion (from Day 1 of each CTH administration until the end of the CTH cycle) or for use of rescue medications (Day 2 until the end of the CTH cycle). A multivariate regression model was developed to predict uncontrolled CINV event rates per CTH cycle between Groups 1 and 2 matched on CTH emetogenicity distribution in the study follow-up period (first of 8 cycles or 6 months). A subgroup analysis of patients on CTH with the highest risk of nausea and vomiting (highly emetogenic CTH or moderately emetogenic CTH) was also conducted.\nRESULTS: Of 9144 identified patients, 1775 were prescribed palonosetron (Group 1). Group 1 patients were statistically younger (61.2 vs 62.8 years; P \u003c 0.001), composed of more females (57.1% vs 51.9%; P \u003c 0.001) and more whites (72.8% vs 71.4%; all races P \u003c 0.001), received more highly emetogenic CTH treatments (43.3% vs 28.5%; all CTH P \u003c 0.001), and had more lung (26.1% vs 22.4%) and breast cancer patients (19.3% vs 15.3%; all cancer P \u003c 0.001). The regression model predicted a 13.7% decrease in CINV event rate per CTH cycle for Group 1 versus Group 2. For Subgroup 1, the model predicted a 12.5% decrease in the CINV event rate per cycle in Group 1 patients versus those in Group 2.\nCONCLUSIONS: In this study, patients with cancer who were treated with CTH and on antiemetic prophylaxis using palonosetron were found to have significantly lower CINV event rates than those receiving other 5-HT(3) receptor antagonists.","tracks":[{"project":"Allie","denotations":[{"id":"SS1_21635990_2_0","span":{"begin":365,"end":405},"obj":"expanded"},{"id":"SS2_21635990_2_0","span":{"begin":407,"end":411},"obj":"abbr"},{"id":"SS1_21635990_2_1","span":{"begin":365,"end":377},"obj":"expanded"},{"id":"SS2_21635990_2_1","span":{"begin":591,"end":594},"obj":"abbr"},{"id":"SS1_21635990_7_0","span":{"begin":1368,"end":1408},"obj":"expanded"},{"id":"SS2_21635990_7_0","span":{"begin":1410,"end":1413},"obj":"abbr"}],"relations":[{"id":"AE1_21635990_2_0","pred":"abbreviatedTo","subj":"SS1_21635990_2_0","obj":"SS2_21635990_2_0"},{"id":"AE1_21635990_2_1","pred":"abbreviatedTo","subj":"SS1_21635990_2_1","obj":"SS2_21635990_2_1"},{"id":"AE1_21635990_7_0","pred":"abbreviatedTo","subj":"SS1_21635990_7_0","obj":"SS2_21635990_7_0"}],"attributes":[{"subj":"SS1_21635990_2_0","pred":"source","obj":"Allie"},{"subj":"SS2_21635990_2_0","pred":"source","obj":"Allie"},{"subj":"SS1_21635990_2_1","pred":"source","obj":"Allie"},{"subj":"SS2_21635990_2_1","pred":"source","obj":"Allie"},{"subj":"SS1_21635990_7_0","pred":"source","obj":"Allie"},{"subj":"SS2_21635990_7_0","pred":"source","obj":"Allie"}]},{"project":"PubmedHPO","denotations":[{"id":"T1","span":{"begin":386,"end":392},"obj":"HP_0002018"},{"id":"T2","span":{"begin":397,"end":405},"obj":"HP_0002013"},{"id":"T3","span":{"begin":552,"end":558},"obj":"HP_0002664"}],"attributes":[{"subj":"T1","pred":"source","obj":"PubmedHPO"},{"subj":"T2","pred":"source","obj":"PubmedHPO"},{"subj":"T3","pred":"source","obj":"PubmedHPO"}]},{"project":"PubMed_Structured_Abstracts","denotations":[{"id":"T1","span":{"begin":200,"end":596},"obj":"BACKGROUND"},{"id":"T2","span":{"begin":608,"end":1011},"obj":"OBJECTIVE"},{"id":"T3","span":{"begin":1021,"end":1998},"obj":"METHODS"},{"id":"T4","span":{"begin":2008,"end":2692},"obj":"RESULTS"},{"id":"T5","span":{"begin":2706,"end":2929},"obj":"CONCLUSIONS"}],"attributes":[{"subj":"T1","pred":"source","obj":"PubMed_Structured_Abstracts"},{"subj":"T2","pred":"source","obj":"PubMed_Structured_Abstracts"},{"subj":"T3","pred":"source","obj":"PubMed_Structured_Abstracts"},{"subj":"T4","pred":"source","obj":"PubMed_Structured_Abstracts"},{"subj":"T5","pred":"source","obj":"PubMed_Structured_Abstracts"}]}],"config":{"attribute types":[{"pred":"source","value type":"selection","values":[{"id":"Allie","color":"#a393ec","default":true},{"id":"PubmedHPO","color":"#9cec93"},{"id":"PubMed_Structured_Abstracts","color":"#ec93b6"}]}]}}